{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:06:14Z","timestamp":1793300774051,"version":"4.5.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n There is a paucity of efficacious antimicrobials (especially oral) against clinically relevant species of\n Nocardia<\/jats:named-content>\n . To date, all species of\n Nocardia<\/jats:named-content>\n have been susceptible to linezolid, the first commercially available oxazolidinone. Tedizolid is a new oxazolidinone with previously reported improved\n in vitro<\/jats:italic>\n and\n in vivo<\/jats:italic>\n (intracellular) potency against multidrug-resistant strains of\n Mycobacterium<\/jats:named-content>\n sp. and\n Nocardia brasiliensis<\/jats:named-content>\n . Using the current Clinical and Laboratory Standards Institute-recommended broth microdilution method, 101 isolates of\n Nocardia<\/jats:named-content>\n spp., including 29\n Nocardia cyriacigeorgica<\/jats:named-content>\n , 17\n Nocardia farcinica<\/jats:named-content>\n , 13\n Nocardia nova<\/jats:named-content>\n complex, 21\n Nocardia brasiliensis<\/jats:named-content>\n , 5\n Nocardia pseudobrasiliensis<\/jats:named-content>\n , and 5\n Nocardia wallacei<\/jats:named-content>\n isolates and 11 isolates of less common species, were tested for susceptibility to tedizolid and linezolid. For the most common clinically significant species of\n Nocardia<\/jats:named-content>\n , tedizolid MIC\n 50<\/jats:sub>\n values were 0.25 \u03bcg\/ml for\n N. nova<\/jats:named-content>\n complex,\n N. brasiliensis<\/jats:named-content>\n ,\n N. pseudobrasiliensis<\/jats:named-content>\n , and\n N. wallacei<\/jats:named-content>\n , compared to linezolid MIC\n 50<\/jats:sub>\n values of 1, 2, 0.5, and 1 \u03bcg\/ml, respectively. Tedizolid and linezolid MIC\n 90<\/jats:sub>\n values were 2 \u03bcg\/ml for\n N. nova<\/jats:named-content>\n complex and\n N. brasiliensis<\/jats:named-content>\n . Tedizolid MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n values for both\n N. cyriacigeorgica<\/jats:named-content>\n and\n N. farcinica<\/jats:named-content>\n were 0.5 \u03bcg\/ml and 1 \u03bcg\/ml, respectively, compared to linezolid MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n values of 2 and 4 \u03bcg\/ml, respectively. Based on MIC\n 90<\/jats:sub>\n values, this study showed that tedizolid was 2- to 3-fold more active than linezolid\n in vitro<\/jats:italic>\n against most common species of\n Nocardia<\/jats:named-content>\n , with the exception of the\n N. nova<\/jats:named-content>\n complex and\n N. brasiliensis<\/jats:named-content>\n , for which values were the same. These results may warrant evaluation of tedizolid as a potential treatment option for\n Nocardia<\/jats:named-content>\n infections.\n <\/jats:p>","DOI":"10.1128\/aac.01537-17","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:40:23Z","timestamp":1505781623000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["In Vitro<\/i>\n Susceptibility Testing of Tedizolid against Isolates of Nocardia"],"prefix":"10.1128","volume":"61","author":[{"given":"Barbara A.","family":"Brown-Elliott","sequence":"first","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Department of Microbiology, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Department of Microbiology, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.2.259-282.2006"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/345907"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1295-1297.2001"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-13-13"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp314"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/156720110791560946"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00571-06"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.660250"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit616"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr403"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00859-08"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302109200"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.03.006"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00076-10"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1337"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.255"},{"key":"e_1_3_3_18_2","volume-title":"Safety and tolerability of long term use of tedizolid for treatment of nontuberculous mycobacterial infections, poster 577","author":"Kim T","year":"2016","unstructured":"Kim T WillsAB MarkusB Daniel-WaymanS PrevotsDR OlivierKN. 2016. Safety and tolerability of long term use of tedizolid for treatment of nontuberculous mycobacterial infections, poster 577. ID Week, New Orleans, LA, 26 to 30 October 2016. https:\/\/idsa.confex.com\/idsa\/2016\/webprogram\/Handout\/id5538\/POSTER69_577.pdf."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw484"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp267"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit615"},{"key":"e_1_3_3_22_2","volume-title":"Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline. CLSI document MM18-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00155-06"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/17.19.7843"},{"key":"e_1_3_3_25_2","volume-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard\u20142nd ed","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard\u20142nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01537-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01537-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:47:17Z","timestamp":1645476437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01537-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1128\/AAC.01537-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01537-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"2017-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01537-17"}}